JOSHUA B SUNDHAR

Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology VOORHEES, NJ NPI 1760623193

General Payments — all program years on this page

$183,135.62

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 391
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $1,528.39 across 18 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Amgen Inc. $891.847
ABBVIE INC. $274.064
GlaxoSmithKline, LLC. $247.794
Janssen Biotech, Inc. $96.522
Acerta Pharma LLC $18.181

By program year

Program yearAmountRecords
2018 $47,786.2467
2019 $65,717.63125
2020 $32,817.1360
2021 $18,724.3958
2022 $11,501.9540
2023 $5,059.8923
2024 $1,528.3918

Records — PY2024 (18)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1078377185 Janssen Biotech, Inc. $79.99 04/30/2024 Education Undisputed 01/23/2026 View at CMS
1078377416 Janssen Biotech, Inc. $16.53 02/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104589358 AstraZeneca Pharmaceuticals LP $18.18 08/07/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1106183661 ABBVIE INC. $15.78 04/23/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1106183663 ABBVIE INC. $120.29 05/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1106183665 ABBVIE INC. $127.56 10/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1106183667 ABBVIE INC. $10.43 10/28/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1111718913 Amgen Inc. $14.57 03/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1111718915 Amgen Inc. $124.56 01/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1111718917 Amgen Inc. $13.05 05/28/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1111718919 Amgen Inc. $14.67 08/27/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1111718921 Amgen Inc. $124.99 10/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116391758 GlaxoSmithKline, LLC. $3.10 01/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116565954 GlaxoSmithKline, LLC. $3.37 04/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116577414 GlaxoSmithKline, LLC. $119.22 05/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116619003 GlaxoSmithKline, LLC. $122.10 08/07/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117394098 Amgen Inc. $300.00 08/22/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 View at CMS
1117394100 Amgen Inc. $300.00 11/21/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.